×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
SLS – sellas life sciences group, inc. (US:NYSE)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
SLS
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
3/22
07:36 am
sls
Assessing SELLAS Life Sciences Group (SLS) Valuation After Its Sharp Recent Share Price Run [Yahoo! Finance]
High
Report
Assessing SELLAS Life Sciences Group (SLS) Valuation After Its Sharp Recent Share Price Run [Yahoo! Finance]
3/20
08:22 am
sls
SELLAS Stock Up 346% in a Year as Cancer Vaccine Trial Nears Its Final 8 Deaths [Yahoo! Finance]
Medium
Report
SELLAS Stock Up 346% in a Year as Cancer Vaccine Trial Nears Its Final 8 Deaths [Yahoo! Finance]
3/19
04:55 pm
sls
SELLAS Life Sciences Reports Full Year 2025 Financial Results and Provides Corporate Update [Yahoo! Finance]
Medium
Report
SELLAS Life Sciences Reports Full Year 2025 Financial Results and Provides Corporate Update [Yahoo! Finance]
3/19
04:45 pm
sls
SELLAS Life Sciences GAAP EPS of -$0.25 beats by $0.01 [Seeking Alpha]
Medium
Report
SELLAS Life Sciences GAAP EPS of -$0.25 beats by $0.01 [Seeking Alpha]
3/19
04:05 pm
sls
SELLAS Life Sciences Reports Full Year 2025 Financial Results and Provides Corporate Update
Medium
Report
SELLAS Life Sciences Reports Full Year 2025 Financial Results and Provides Corporate Update
3/17
05:14 pm
sls
SELLAS Life Sciences to Present Preclinical Data Highlighting Potent Activity of SLS009 in AML at the 2026 AACR Conference [Yahoo! Finance]
Medium
Report
SELLAS Life Sciences to Present Preclinical Data Highlighting Potent Activity of SLS009 in AML at the 2026 AACR Conference [Yahoo! Finance]
3/17
04:30 pm
sls
SELLAS Life Sciences to Present Preclinical Data Highlighting Potent Activity of SLS009 in AML at the 2026 AACR Conference
Low
Report
SELLAS Life Sciences to Present Preclinical Data Highlighting Potent Activity of SLS009 in AML at the 2026 AACR Conference
3/16
08:04 am
sls
SELLAS Life Sciences Group (SLS) had its price target raised by Maxim Group from $7.00 to $10.00. They now have a "buy" rating on the stock.
Low
Report
SELLAS Life Sciences Group (SLS) had its price target raised by Maxim Group from $7.00 to $10.00. They now have a "buy" rating on the stock.
Date
Time
Symbol
Company Name
Action
%Chg
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
3/20
05:01 pm
sls
Form S-3ASR SELLAS Life Sciences
High
Report
Form S-3ASR SELLAS Life Sciences
3/19
04:09 pm
sls
Form 8-K SELLAS Life Sciences For: Mar 19
Medium
Report
Form 8-K SELLAS Life Sciences For: Mar 19
3/19
04:01 pm
sls
Form 10-K SELLAS Life Sciences For: Dec 31
Medium
Report
Form 10-K SELLAS Life Sciences For: Dec 31
3/11
04:06 pm
sls
Form 8-K SELLAS Life Sciences For: Mar 11
Medium
Report
Form 8-K SELLAS Life Sciences For: Mar 11
2/17
10:34 am
sls
Form SCHEDULE 13G/A SELLAS Life Sciences Filed by: Anson Funds Management LP
Medium
Report
Form SCHEDULE 13G/A SELLAS Life Sciences Filed by: Anson Funds Management LP
1/30
04:15 pm
sls
Form SCHEDULE 13G/A SELLAS Life Sciences Filed by: HIGHBRIDGE CAPITAL MANAGEMENT LLC
Medium
Report
Form SCHEDULE 13G/A SELLAS Life Sciences Filed by: HIGHBRIDGE CAPITAL MANAGEMENT LLC
1/9
04:44 pm
sls
Form 4 SELLAS Life Sciences For: Jan 07 Filed by: Varian John
High
Report
Form 4 SELLAS Life Sciences For: Jan 07 Filed by: Varian John
1/9
04:39 pm
sls
Form 4 SELLAS Life Sciences For: Jan 07 Filed by: VAN NOSTRAND ROBERT L
High
Report
Form 4 SELLAS Life Sciences For: Jan 07 Filed by: VAN NOSTRAND ROBERT L
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
7/2
Form 8-K SELLAS Life Sciences For: Jul 01
37.1%
5/31 Form 8-K SELLAS Life Sciences For: May 31 10.3%
8/14 Form 8-K SELLAS Life Sciences For: Aug 14 7.5%
7/15 Form 8-K SELLAS Life Sciences For: Jul 12 6.8%
8/5 Form DEF 14A SELLAS Life Sciences For: Sep 10 4.5%
4/28 SELLAS Releases Annual Letter to Shareholders 4.1%
11/25 Form 8-K SELLAS Life Sciences For: Nov 25 3.1%
2/26 SELLAS Announces Positive Follow-Up Phase 1/2 Clinical Data for Galinpepimut-S (GPS) in Acute Myeloid Leukemia (AML) 1.9%
1/17 Form SC 13G SELLAS Life Sciences Filed by: CVI Investments, Inc. 1.3%
3/16 Form 4 SELLAS Life Sciences For: Mar 12 Filed by: Burns John Thomas 1.1%
5/31 Form 8-K SELLAS Life Sciences For: May 31 10.3%
8/14 Form 8-K SELLAS Life Sciences For: Aug 14 7.5%
7/15 Form 8-K SELLAS Life Sciences For: Jul 12 6.8%
8/5 Form DEF 14A SELLAS Life Sciences For: Sep 10 4.5%
4/28 SELLAS Releases Annual Letter to Shareholders 4.1%
11/25 Form 8-K SELLAS Life Sciences For: Nov 25 3.1%
2/26 SELLAS Announces Positive Follow-Up Phase 1/2 Clinical Data for Galinpepimut-S (GPS) in Acute Myeloid Leukemia (AML) 1.9%
1/17 Form SC 13G SELLAS Life Sciences Filed by: CVI Investments, Inc. 1.3%
3/16 Form 4 SELLAS Life Sciences For: Mar 12 Filed by: Burns John Thomas 1.1%
TOP News Decliners
6/14
Form EFFECT SELLAS Life Sciences
-55.6%
11/6 SELLAS Announces Reverse Stock Split -27.8%
5/23 Form S-1 SELLAS Life Sciences -27.0%
7/9 Form 8-K SELLAS Life Sciences For: Jul 08 -19.5%
1/13 SELLAS Highlights Clinical Development Progress and Expected 2020 Milestones -19.4%
11/14 Form 8-K SELLAS Life Sciences For: Nov 14 -18.3%
7/31 SELLAS Advances Galinpepimut-S (GPS) in Combination with KEYTRUDA® (pembrolizumab) Program with Dosing of First Patient in Phase 1/2 Basket Study -18.1%
7/9 Form 8-K SELLAS Life Sciences For: Jul 09 -15.3%
1/8 SELLAS Commences Pivotal Phase 3 REGAL Study of Galinpepimut-S (GPS) in Patients with Acute Myeloid Leukemia (AML) -12.9%
6/6 Form S-1/A SELLAS Life Sciences -10.3%
11/6 SELLAS Announces Reverse Stock Split -27.8%
5/23 Form S-1 SELLAS Life Sciences -27.0%
7/9 Form 8-K SELLAS Life Sciences For: Jul 08 -19.5%
1/13 SELLAS Highlights Clinical Development Progress and Expected 2020 Milestones -19.4%
11/14 Form 8-K SELLAS Life Sciences For: Nov 14 -18.3%
7/31 SELLAS Advances Galinpepimut-S (GPS) in Combination with KEYTRUDA® (pembrolizumab) Program with Dosing of First Patient in Phase 1/2 Basket Study -18.1%
7/9 Form 8-K SELLAS Life Sciences For: Jul 09 -15.3%
1/8 SELLAS Commences Pivotal Phase 3 REGAL Study of Galinpepimut-S (GPS) in Patients with Acute Myeloid Leukemia (AML) -12.9%
6/6 Form S-1/A SELLAS Life Sciences -10.3%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: